JP2019513694A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019513694A5 JP2019513694A5 JP2018544781A JP2018544781A JP2019513694A5 JP 2019513694 A5 JP2019513694 A5 JP 2019513694A5 JP 2018544781 A JP2018544781 A JP 2018544781A JP 2018544781 A JP2018544781 A JP 2018544781A JP 2019513694 A5 JP2019513694 A5 JP 2019513694A5
- Authority
- JP
- Japan
- Prior art keywords
- idh2
- flt3
- mutant allele
- pharmaceutical composition
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108700028369 Alleles Proteins 0.000 claims description 51
- 206010028980 Neoplasm Diseases 0.000 claims description 45
- 238000000034 method Methods 0.000 claims description 44
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims description 40
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims description 40
- 239000003112 inhibitor Substances 0.000 claims description 33
- 201000011510 cancer Diseases 0.000 claims description 31
- 229940125904 compound 1 Drugs 0.000 claims description 21
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 18
- 206010066476 Haematological malignancy Diseases 0.000 claims description 16
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 11
- 239000002207 metabolite Substances 0.000 claims description 10
- 239000000651 prodrug Substances 0.000 claims description 10
- 229940002612 prodrug Drugs 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 239000012453 solvate Substances 0.000 claims description 10
- 238000006467 substitution reaction Methods 0.000 claims description 10
- 206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 claims description 9
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims description 8
- UIARLYUEJFELEN-LROUJFHJSA-N LSM-1231 Chemical compound C12=C3N4C5=CC=CC=C5C3=C3C(=O)NCC3=C2C2=CC=CC=C2N1[C@]1(C)[C@](CO)(O)C[C@H]4O1 UIARLYUEJFELEN-LROUJFHJSA-N 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 229960001796 sunitinib Drugs 0.000 claims description 8
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 8
- 102000012011 Isocitrate Dehydrogenase Human genes 0.000 claims description 7
- 108010075869 Isocitrate Dehydrogenase Proteins 0.000 claims description 7
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 7
- 230000036210 malignancy Effects 0.000 claims description 7
- 239000012472 biological sample Substances 0.000 claims description 6
- DYLUUSLLRIQKOE-UHFFFAOYSA-N enasidenib Chemical compound N=1C(C=2N=C(C=CC=2)C(F)(F)F)=NC(NCC(C)(O)C)=NC=1NC1=CC=NC(C(F)(F)F)=C1 DYLUUSLLRIQKOE-UHFFFAOYSA-N 0.000 claims description 6
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 4
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 4
- GKEYKDOLBLYGRB-LGMDPLHJSA-N 5-[2-(diethylamino)ethyl]-2-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-3-methyl-6,7-dihydro-1h-pyrrolo[3,2-c]pyridin-4-one Chemical compound O=C\1NC2=CC=C(F)C=C2C/1=C/C(N1)=C(C)C2=C1CCN(CCN(CC)CC)C2=O GKEYKDOLBLYGRB-LGMDPLHJSA-N 0.000 claims description 4
- WVXNSAVVKYZVOE-UHFFFAOYSA-N DCC-2036 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=C4C=CC=NC4=CC=3)=CC=2)=C1 WVXNSAVVKYZVOE-UHFFFAOYSA-N 0.000 claims description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- YYLKKYCXAOBSRM-JXMROGBWSA-N [4-[(e)-2-(1h-indazol-3-yl)ethenyl]phenyl]-piperazin-1-ylmethanone Chemical compound C=1C=C(\C=C\C=2C3=CC=CC=C3NN=2)C=CC=1C(=O)N1CCNCC1 YYLKKYCXAOBSRM-JXMROGBWSA-N 0.000 claims description 4
- 229940125199 famitinib Drugs 0.000 claims description 4
- GYQYAJJFPNQOOW-UHFFFAOYSA-N gilteritinib Chemical compound N1=C(NC2CCOCC2)C(CC)=NC(C(N)=O)=C1NC(C=C1OC)=CC=C1N(CC1)CCC1N1CCN(C)CC1 GYQYAJJFPNQOOW-UHFFFAOYSA-N 0.000 claims description 4
- 229950001845 lestaurtinib Drugs 0.000 claims description 4
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 claims description 4
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 claims description 4
- JGWRKYUXBBNENE-UHFFFAOYSA-N pexidartinib Chemical compound C1=NC(C(F)(F)F)=CC=C1CNC(N=C1)=CC=C1CC1=CNC2=NC=C(Cl)C=C12 JGWRKYUXBBNENE-UHFFFAOYSA-N 0.000 claims description 4
- PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 claims description 4
- CVWXJKQAOSCOAB-UHFFFAOYSA-N quizartinib Chemical group O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(=CC=2)C=2N=C3N(C4=CC=C(OCCN5CCOCC5)C=C4S3)C=2)=N1 CVWXJKQAOSCOAB-UHFFFAOYSA-N 0.000 claims description 4
- 238000012216 screening Methods 0.000 claims description 4
- IVDHYUQIDRJSTI-UHFFFAOYSA-N sorafenib tosylate Chemical compound [H+].CC1=CC=C(S([O-])(=O)=O)C=C1.C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 IVDHYUQIDRJSTI-UHFFFAOYSA-N 0.000 claims description 4
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 3
- 208000032612 Glial tumor Diseases 0.000 claims description 3
- 206010018338 Glioma Diseases 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 3
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
- 102200116484 rs121913502 Human genes 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 2
- 206010008583 Chloroma Diseases 0.000 claims description 2
- 208000017815 Dendritic cell tumor Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 2
- 238000002648 combination therapy Methods 0.000 claims description 2
- 201000005987 myeloid sarcoma Diseases 0.000 claims description 2
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 claims description 2
- 230000000306 recurrent effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 238000010276 construction Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 0 CC(C)(CNc1nc(Nc2ccnc(*)c2)nc(-c2nc(C(F)(F)F)ccc2)n1)O Chemical compound CC(C)(CNc1nc(Nc2ccnc(*)c2)nc(-c2nc(C(F)(F)F)ccc2)n1)O 0.000 description 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
- 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 201000011649 lymphoblastic lymphoma Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662300673P | 2016-02-26 | 2016-02-26 | |
| US62/300,673 | 2016-02-26 | ||
| PCT/US2016/064615 WO2017146794A1 (en) | 2016-02-26 | 2016-12-02 | Idh2 inhibitors for the treatment of haematological maligancies and solid tumours |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019513694A JP2019513694A (ja) | 2019-05-30 |
| JP2019513694A5 true JP2019513694A5 (enExample) | 2020-01-23 |
| JP6930991B2 JP6930991B2 (ja) | 2021-09-01 |
Family
ID=57610404
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018544835A Expired - Fee Related JP6856657B2 (ja) | 2016-02-26 | 2016-12-02 | 血液学的悪性疾患および固形腫瘍の処置のためのｉｄｈ１阻害剤 |
| JP2018544781A Expired - Fee Related JP6930991B2 (ja) | 2016-02-26 | 2016-12-02 | 血液学的悪性腫瘍及び固形腫瘍の治療のためのｉｄｈ２阻害剤 |
| JP2021044546A Withdrawn JP2021102630A (ja) | 2016-02-26 | 2021-03-18 | 血液学的悪性疾患および固形腫瘍の処置のためのｉｄｈ１阻害剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018544835A Expired - Fee Related JP6856657B2 (ja) | 2016-02-26 | 2016-12-02 | 血液学的悪性疾患および固形腫瘍の処置のためのｉｄｈ１阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021044546A Withdrawn JP2021102630A (ja) | 2016-02-26 | 2021-03-18 | 血液学的悪性疾患および固形腫瘍の処置のためのｉｄｈ１阻害剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20190046512A1 (enExample) |
| EP (2) | EP3419594B1 (enExample) |
| JP (3) | JP6856657B2 (enExample) |
| KR (2) | KR20180114202A (enExample) |
| CN (1) | CN109069410B (enExample) |
| AU (2) | AU2016393870B2 (enExample) |
| CA (2) | CA3015757A1 (enExample) |
| ES (1) | ES2912909T3 (enExample) |
| IL (2) | IL261333B (enExample) |
| MA (1) | MA43640A (enExample) |
| MX (3) | MX390396B (enExample) |
| WO (2) | WO2017146795A1 (enExample) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
| WO2015010297A1 (en) | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| US9968595B2 (en) | 2014-03-14 | 2018-05-15 | Agios Pharmaceuticals, Inc. | Pharmaceutical compositions of therapeutically active compounds |
| EP3201185B1 (en) | 2014-09-19 | 2018-11-21 | Forma Therapeutics, Inc. | Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| AU2015317321B2 (en) | 2014-09-19 | 2020-03-12 | Forma Therapeutics, Inc. | Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors |
| MX372964B (es) | 2014-09-19 | 2020-03-27 | Forma Therapeutics Inc | Derivados de fenil quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh) |
| KR102209667B1 (ko) | 2014-09-19 | 2021-01-29 | 포르마 세라퓨틱스 인크. | 돌연변이-아이소시트레이트 탈수소효소 저해제로서의 피리딘-2(1h)-온 퀴놀린 유도체 |
| EP3200800A1 (en) | 2014-09-29 | 2017-08-09 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| WO2016126798A1 (en) | 2015-02-04 | 2016-08-11 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| US9624216B2 (en) | 2015-04-21 | 2017-04-18 | Forma Therapeutics, Inc. | Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors |
| WO2016171755A1 (en) | 2015-04-21 | 2016-10-27 | Forma Therapeutics, Inc. | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| UA123401C2 (uk) | 2015-10-15 | 2021-03-31 | Аджиос Фармасьютікалз, Інк. | Комбінована терапія для лікування злоякісних пухлин |
| DK3362066T3 (da) | 2015-10-15 | 2021-11-22 | Les Laboratoires Servier Sas | Kombinationsterapi til behandling af maligniteter |
| MX381582B (es) | 2015-10-15 | 2025-03-12 | Celgene Corp | Terapia de combinacion para el tratamiento de neoplasias malignas. |
| CA3001599A1 (en) | 2015-10-15 | 2017-04-20 | Agios Pharmaceuticals, Inc. | Combination therapy for treating malignancies |
| US12282014B2 (en) | 2015-11-19 | 2025-04-22 | Dana-Farber Cancer Institute, Inc. | Methods of identifying compounds that interfere with ERG-driven misguidance of BAF complexes in TMPRSS2-ERG driven prostate cancers |
| US20180042930A1 (en) * | 2016-08-03 | 2018-02-15 | Celgene Corporation | Methods of treatment of malignancies |
| JP2019529534A (ja) | 2016-09-07 | 2019-10-17 | セルジーン コーポレイション | 錠剤組成物 |
| EP3618828B1 (en) | 2017-05-05 | 2023-11-01 | Memorial Sloan Kettering Cancer Center | Methods of treatment of myeloproliferative neoplasm |
| SG11202002753QA (en) | 2017-10-26 | 2020-05-28 | Nat Univ Singapore | A new approach for universal monitoring of minimal residual disease in acute myeloid leukemia |
| WO2019109095A1 (en) * | 2017-12-01 | 2019-06-06 | Beth Israel Deaconess Medical Center, Inc. | Arsenic trioxide and retinoic acid compounds for treatment of idh2-associated disorders |
| US11497752B2 (en) | 2018-01-30 | 2022-11-15 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| EP3746059B1 (en) | 2018-01-31 | 2026-03-04 | Deciphera Pharmaceuticals, LLC | Combination therapy for the treatment of gastrointestinal stromal tumors |
| AU2019216351B2 (en) | 2018-01-31 | 2024-07-25 | Deciphera Pharmaceuticals, Llc | Combination therapy for the treatment of mastocytosis |
| US11013734B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation |
| WO2019222551A1 (en) | 2018-05-16 | 2019-11-21 | Forma Therapeutics, Inc. | Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
| US11311527B2 (en) | 2018-05-16 | 2022-04-26 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) |
| US20210196701A1 (en) | 2018-05-16 | 2021-07-01 | Forma Therapeutics, Inc. | Inhibiting mutant idh-1 |
| US11497743B2 (en) | 2018-05-16 | 2022-11-15 | Forma Therapeutics, Inc. | Treating patients harboring an isocitrate dehydrogenase 1 (IDH-1) mutation |
| US11013733B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1) |
| US11738018B2 (en) | 2018-05-16 | 2023-08-29 | FORMA Therapeuetics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) |
| US10980788B2 (en) | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
| IL315423B1 (en) * | 2018-07-06 | 2026-04-01 | Servier Lab | Ivusidnib forms and pharmaceutical preparations |
| US20210299233A1 (en) * | 2018-07-12 | 2021-09-30 | The Children's Medical Center Corporation | Method for treating cancer |
| WO2020090968A1 (ja) * | 2018-10-31 | 2020-05-07 | 富士フイルム株式会社 | 抗腫瘍剤を含む造粒物 |
| US20220017489A1 (en) * | 2018-11-02 | 2022-01-20 | Celgene Corporation | Solid dispersions for treatment of cancer |
| US20220017490A1 (en) | 2018-11-02 | 2022-01-20 | Celgene Corporation | Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof |
| US12215094B2 (en) | 2018-11-02 | 2025-02-04 | Celgene Corporation | Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol |
| WO2020117867A1 (en) * | 2018-12-03 | 2020-06-11 | Beth Israel-Deaconess Medical Center, Inc. | Darinaparsin and retinoic acid compounds for treatment of idh-associated disorders |
| WO2020117868A1 (en) * | 2018-12-03 | 2020-06-11 | Beth Israel-Deaconess Medical Center, Inc. | Arsenic compounds and retinoic acid compounds for treatment of idh-associated disorders |
| WO2020160100A1 (en) | 2019-01-29 | 2020-08-06 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2020185812A1 (en) | 2019-03-11 | 2020-09-17 | Teva Pharmaceuticals International Gmbh | Solid state forms of ripretinib |
| KR102035479B1 (ko) * | 2019-04-12 | 2019-10-23 | 한국지질자원연구원 | 점토광물 복합체를 포함하는 방출성이 제어된 경구투여용 조성물 |
| FI4013412T3 (fi) | 2019-08-12 | 2026-03-24 | Deciphera Pharmaceuticals Llc | Ripretinibi ruoansulatuskanavan stroomakasvaimien hoitoon |
| TWI878335B (zh) | 2019-08-12 | 2025-04-01 | 美商迪賽孚爾製藥有限公司 | 治療胃腸道基質瘤方法 |
| WO2021071678A1 (en) | 2019-10-07 | 2021-04-15 | University Hospitals Cleveland Medical Center | Methods for treating wild type isocitrate dehydrogenase 1 cancers |
| CN112773797A (zh) * | 2019-11-11 | 2021-05-11 | 江苏恒瑞医药股份有限公司 | 一种吡咯并六元杂环化合物在制备治疗flt3突变的肿瘤的药物中的用途 |
| WO2021097160A1 (en) | 2019-11-14 | 2021-05-20 | Celgene Corporation | Pediatric formulations for treatment of cancer |
| PL4084779T3 (pl) | 2019-12-30 | 2025-02-24 | Deciphera Pharmaceuticals, Llc | Kompozycje 1-(4-bromo-5-(1-etylo-7-(metyloamino)-2-okso-1,2-dihydro-1,6-naftyrydyn-3-ylo)-2-fluorofenylo)-3-fenylomocznika |
| WO2021138391A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
| AU2020419197B2 (en) | 2019-12-30 | 2023-08-31 | Deciphera Pharmaceuticals, Llc | Amorphous kinase inhibitor formulations and methods of use thereof |
| BR112022015004A2 (pt) | 2020-01-29 | 2022-09-20 | Foghorn Therapeutics Inc | Composto, composição farmacêutica, métodos para diminuir a atividade de um complexo baf, induzir apoptose, reduzir o crescimento tumoral, suprimir a progressão e a colonização metastática do câncer e reduzir o nível e/ou a atividade de brg1 e/ou brm em um câncer e métodos de tratamento e de inibição de brm e brg1 |
| US12014835B2 (en) | 2020-02-19 | 2024-06-18 | Vanderbilt University | Methods for evaluating therapeutic benefit of combination therapies |
| ES2981250T3 (es) * | 2020-03-23 | 2024-10-08 | Lilly Co Eli | Terapia combinada con un inhibidor de IDH mutante |
| US12383555B2 (en) | 2020-05-20 | 2025-08-12 | Foghorn Therapeutics Inc. | Methods of treating cancers |
| WO2022056453A1 (en) * | 2020-09-14 | 2022-03-17 | Totus Medicines Inc. | Therapeutic conjugates |
| CN114681451B (zh) * | 2020-11-10 | 2023-11-03 | 华熙生物科技股份有限公司 | 透明质酸或其盐和/或海藻糖的组合物及其在稳定麦角硫因中的用途 |
| JP2024509268A (ja) | 2021-03-09 | 2024-02-29 | フォグホーン セラピューティクス インコーポレイテッド | 結晶形、それらを含有する組成物、及びそれらの使用方法 |
| CA3242316A1 (en) | 2021-12-30 | 2023-07-06 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of flt3 |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
| WO2024249769A2 (en) * | 2023-06-02 | 2024-12-05 | Foghorn Therapeutics Inc. | Combination therapy for treating hematological cancers |
| CN117838863B (zh) * | 2023-12-26 | 2025-03-11 | 厦门大学 | 一种抑制d2hgdh的核酸分子、抑制剂及其用途 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
| ES2248908T7 (es) | 1997-06-06 | 2014-11-24 | Depomed, Inc. | Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles |
| PT1251832E (pt) | 2000-02-04 | 2007-01-31 | Depomed Inc | Forma de dosagem constituída por invólucro-e-núcleo que conduz a uma libertação do fármaco de ordem zero |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| ES2740424T3 (es) | 2009-03-13 | 2020-02-05 | Agios Pharmaceuticals Inc | Métodos y composiciones para trastornos relacionados con la proliferación celular |
| AU2010228982B2 (en) * | 2009-03-23 | 2015-05-14 | Ambit Biosciences Corporation | Methods of treatment using combination therapy |
| EP3064595B1 (en) | 2009-10-21 | 2019-02-27 | Agios Pharmaceuticals, Inc. | Methods for cell-proliferation-related disorders |
| LT2800743T (lt) | 2012-01-06 | 2018-06-25 | Agios Pharmaceuticals, Inc. | Terapiškai aktyvūs junginiai ir jų panaudojimo būdai |
| US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
| BR112015016282A2 (en) * | 2013-01-07 | 2017-07-11 | Arog Pharmaceuticals, Inc. | crenolanib for treatment of mutated flt3 proliferative disorders |
| ES2807582T3 (es) | 2013-07-11 | 2021-02-23 | Agios Pharmaceuticals Inc | Compuestos N,6-bis(aril o heteroaril)-1,3,5-triazina-2,4-diamina como inhibidores de mutantes IDH2 para el tratamiento del cáncer |
| WO2015017821A2 (en) | 2013-08-02 | 2015-02-05 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| CA2842635A1 (en) | 2014-01-20 | 2015-07-20 | University Health Network | Pre-cancerous cells and their identification in the prevention and treatment of cancer |
| WO2015127173A1 (en) * | 2014-02-20 | 2015-08-27 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| WO2015127172A1 (en) * | 2014-02-20 | 2015-08-27 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| EA202090098A1 (ru) | 2014-03-14 | 2020-11-30 | Аджиос Фармасьютикалз, Инк | Фармацевтические композиции терапевтически активных соединений |
| US9968595B2 (en) * | 2014-03-14 | 2018-05-15 | Agios Pharmaceuticals, Inc. | Pharmaceutical compositions of therapeutically active compounds |
| EP3200800A1 (en) | 2014-09-29 | 2017-08-09 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| WO2016126798A1 (en) | 2015-02-04 | 2016-08-11 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| EP3331866B1 (en) | 2015-08-05 | 2023-07-26 | Les Laboratoires Servier | Methods of preparing a 6-heteroaryl-1,3,5-triazine-2,4-diol and a 6-heteroaryl-1,3,5-triazine-2,4-diamine |
-
2016
- 2016-12-02 WO PCT/US2016/064845 patent/WO2017146795A1/en not_active Ceased
- 2016-12-02 MA MA043640A patent/MA43640A/fr unknown
- 2016-12-02 WO PCT/US2016/064615 patent/WO2017146794A1/en not_active Ceased
- 2016-12-02 MX MX2018010252A patent/MX390396B/es unknown
- 2016-12-02 AU AU2016393870A patent/AU2016393870B2/en not_active Expired - Fee Related
- 2016-12-02 AU AU2016393869A patent/AU2016393869B2/en not_active Ceased
- 2016-12-02 CN CN201680082688.XA patent/CN109069410B/zh not_active Expired - Fee Related
- 2016-12-02 JP JP2018544835A patent/JP6856657B2/ja not_active Expired - Fee Related
- 2016-12-02 KR KR1020187027740A patent/KR20180114202A/ko not_active Ceased
- 2016-12-02 KR KR1020187024384A patent/KR20180113540A/ko not_active Ceased
- 2016-12-02 US US16/079,802 patent/US20190046512A1/en not_active Abandoned
- 2016-12-02 EP EP16819389.4A patent/EP3419594B1/en active Active
- 2016-12-02 CA CA3015757A patent/CA3015757A1/en active Pending
- 2016-12-02 MX MX2018010261A patent/MX391470B/es unknown
- 2016-12-02 JP JP2018544781A patent/JP6930991B2/ja not_active Expired - Fee Related
- 2016-12-02 US US15/368,405 patent/US10137130B2/en active Active
- 2016-12-02 EP EP16816810.2A patent/EP3419593B1/en not_active Not-in-force
- 2016-12-02 CA CA3015753A patent/CA3015753A1/en not_active Abandoned
- 2016-12-02 ES ES16816810T patent/ES2912909T3/es active Active
-
2018
- 2018-08-23 IL IL261333A patent/IL261333B/en unknown
- 2018-08-23 IL IL261353A patent/IL261353A/en unknown
- 2018-08-24 MX MX2021007790A patent/MX2021007790A/es unknown
-
2020
- 2020-05-07 US US16/869,238 patent/US20200261434A1/en not_active Abandoned
-
2021
- 2021-03-18 JP JP2021044546A patent/JP2021102630A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019502669A5 (enExample) | ||
| JP2021098740A5 (enExample) | ||
| JP2018535951A5 (enExample) | ||
| JP2019510746A5 (enExample) | ||
| Lankheet et al. | Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib | |
| Olivieri et al. | Dasatinib: a new step in molecular target therapy | |
| Gerber et al. | Management and future directions in non-small cell lung cancer with known activating mutations | |
| Lazăr et al. | New advances in targeted gastric cancer treatment | |
| JP2019507721A5 (enExample) | ||
| Atkins et al. | Sunitinib maleate | |
| JP2019142930A5 (enExample) | ||
| JP2018534288A5 (enExample) | ||
| JP2020147571A5 (enExample) | ||
| Ikeda et al. | Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine | |
| CN115485262B (zh) | 低氧诱导因子-2(α)抑制剂及其在疾病治疗中的用途 | |
| JP2016527279A5 (enExample) | ||
| KR20120115237A (ko) | 암 치료 방법 및 조성물 | |
| CA3015753A1 (en) | Idh2 inhibitors for the treatment of haematological maligancies and solid tumours | |
| JP2018526376A5 (enExample) | ||
| US11833154B2 (en) | Methods of treatment of myeloproliferative neoplasm | |
| JP2014505658A5 (enExample) | ||
| IL268307B1 (en) | An inhibitor of ATR kinase for use in a method of treating hyperproliferative disease | |
| JPWO2017200016A1 (ja) | Ｅｇｆｒ−ｔｋｉ耐性を獲得した肺癌の治療薬 | |
| Lamba et al. | Recent advances and novel agents for gastrointestinal stromal tumor (GIST) | |
| WO2018122168A1 (en) | Combinations of bub1 kinase and parp inhibitors |